Zevra Therapeutics (ZVRA) Cash & Equivalents (2014 - 2026)

Zevra Therapeutics has reported Cash & Equivalents for 13 years, with the latest figure at $95.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 156.01% year-over-year to $95.6 million; the trailing twelve-month figure through Mar 2026 stood at $95.6 million (up 156.01% YoY), and the FY2025 full-year result was $62.4 million, up 84.72% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $95.6 million, up from $62.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $95.6 million in Q1 2026, with the low at $33.8 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $55.3 million across 5 years, with a median of $54.0 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 46.72% — and 2026, when it jumped 156.01%.
• Zevra Therapeutics' Cash & Equivalents stood at $65.5 million in 2022, then sank by 34.24% to $43.0 million in 2023, then retreated by 21.52% to $33.8 million in 2024, then soared by 84.72% to $62.4 million in 2025, then surged by 53.18% to $95.6 million in 2026.
• The last three Cash & Equivalents figures came in at $95.6 million (Q1 2026), $62.4 million (Q4 2025), and $54.4 million (Q3 2025), per Business Quant data.